871507-80-1

Usage

Uses

Used in Organic Synthesis:
2-Phenyl-8-Bromquinoline is used as a key intermediate in the synthesis of various organic compounds due to its reactive bromine atom and the presence of the phenyl group, which can be further functionalized to yield a range of products.
Used in Medicinal Chemistry:
2-Phenyl-8-Bromquinoline is used as a potential candidate for drug development in medicinal chemistry. Its unique structure and potential biological activities make it a promising scaffold for the design and synthesis of new therapeutic agents.
Used in Pharmaceutical Industry:
2-Phenyl-8-Bromquinoline is used as a building block for the development of novel pharmaceuticals, particularly in the areas of anti-inflammatory, antimicrobial, and anticancer agents, owing to its potential pharmacological properties and the possibility of modifying its structure to enhance its therapeutic effects.
Used in Research and Development:
2-Phenyl-8-Bromquinoline is used as a research tool in academic and industrial laboratories to explore its chemical reactivity, biological activities, and potential applications in drug discovery and development. Its unique structure provides a platform for understanding the structure-activity relationships and optimizing its properties for specific therapeutic targets.

Upstream product

• 67805-67-8 8-bromo-1H-quinoline-2-one 
• 871507-79-8 2,8-dibromoquinoline 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1418268-29-7 N-(2,6-diisopropylphenyl)-2-phenyl-8-quinolinamine 
• 1418268-34-4 C₄₁H₄₀HfN₂ 
• 1418268-33-3 C₄₁H₄₀N₂Zr 

Relevant academic research and scientific papers

5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS

The present invention relates to novel aminopyridine derivatives of the general formula (I) and pharmaceutical compositions comprising these compounds, as well as their therapeutic use, particularly as neuropeptide FF (NPFF) receptor antagonists, including, e.g., for the treatment or prevention of pain, opioid-induced hyperalgesia, or addiction.

An Unexpected Construction of 2-Arylquinolines from N-Cinnamylanilines through sp3 Ci-H Aerobic Oxidation Induced by a Catalytic Radical Cation Salt

An unexpected reaction of cinnamylanilines was achieved through the radical cation salt-induced aerobic oxidation of sp3 C-H bonds, providing a series of 2-arylquinolines. The mechanistic study shows that the cinnamylaniline was oxidized to an imine, which was attacked by the aniline generated through decomposition of the corresponding imine. After further intramolecular cyclization and aromatization, 2-arylquinolines were obtained. This reaction provides a new method to construct 2-arylquinolines from readily accessible starting materials.

Zirconium and hafnium complexes based on 2-aryl-8-arylaminoquinoline ligands: Synthesis, molecular structure, and catalytic performance in ethylene copolymerization

A general and efficient approach toward new zirconium and hafnium complexes based on 2-aryl-8-arylaminoquinoline ligands was developed. These precursors, when activated with MAO/borate cocatalyst and supported on silica, result in active olefin polymeriza

Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor

Poly(ADP-ribose)polymerase-1 is an important target enzyme in drug design; inhibitors have a wide variety of therapeutic activities. A series of quinoline-8-carboxamides was designed to maintain the required pharmacophore conformation through an intramolecular hydrogen bond. 3-Substituted quinoline-8-carboxamides were synthesized by Pd-catalyzed couplings (Suzuki, Sonogashira, Stille) to 3-iodoquinoline-8-carboxamide, an efficient process that introduces diversity in the final step. 2-Substituted quinoline-8-carboxamides were prepared by selective Pd-catalyzed couplings at the 2-position of 2,8-dibromoquinoline, followed by lithium-bromine exchange of the intermediate 2-(alkyl/aryl)-8-bromoquinolines and reaction with trimethylsilyl isocyanate. The intramolecular hydrogen bond was confirmed by X-ray and by NMR. The SAR of the 3-substituted compounds for inhibition of human recombinant PARP-1 activity showed a requirement for a small narrow group. Substituents in the 2-position increased potency, with the most active 2-methylquinoline-8-carboxamide having IC50 = 500 nM (IC50 = 1.8 μM for 5-aminoisoquinolin-1- one (5-AIQ, a standard water-soluble inhibitor)).

New tridentate cyclometalated platinum(II) and palladium(II) complexes of N,2-diphenyl-8-quinolinamine: Syntheses, crystal structures, and photophysical properties

A new tridentate cyclometalated platinum(II) complex derived from N,2-diphenyl-8-quinolinamine, which consists of two crystallographic independent molecules with two intermolecular N-H-Cl-Pt hydrogen bonds forming a dimer, exhibited a low-energy luminesce